Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchSipavibartSipavibart (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 
    
  
Sipavibart for COVID-19
2 studies with >2,000 patients
Hospital Icon Control
Hospital Icon Sipavibart Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Sipavibart studies. Aug 2025. c19early.org
0 0.5 1 1.5+ All studies -241% Mortality -241% Cases 33% RCTs -241% RCT mortality -241% Prophylaxis -241% Favorssipavibart Favorscontrol
mAb use may create new variants that spread globally1-3, and may be associated with prolonged viral loads, clinical deterioration, and immune escape2,4-6. Recent:
Haidar
Haars.
Jul 31
Haidar et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(24)00804-1 Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
236% higher mortality (p=0.09), 1% lower hospitalization (p=1), and 32% fewer cases (p=0.0005). RCT 3,349 immunocompromised patients showing lower symptomatic COVID-19 with sipavibart versus a combined comparator group. There was no significant difference for severe COVID-19 or hospitalization. All-cause mortality and adverse events..
May 26
Haars et al., Infectious Diseases, doi:10.1080/23744235.2025.2509011 Dynamics of SARS-CoV-2 variants and mutations in Central Sweden between 2023 and 2024 and their potential implications on monoclonal antibodies pemivibart and sipavibart as PrEP in the region
Analysis of SARS-CoV-2 variants and mutations in central Sweden from October 2023 to October 2024, showing the rise of resistance mutations that likely render monoclonal antibodies sipavibart and pemivibart ineffective.
Sep 30
2024
Planas et al., Pathogens and Immunity, doi:10.20411/pai.v10i1.752 Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies
In Vitro study showing significant escape of SARS-CoV-2 variants KP.1.1, LB.1, and KP.3.3 with monoclonal antibodies pemivibart (VYD222) and sipavibart (AZD3152). Sipavibart lost antiviral efficacy, while pemivibart maintained reduced act..
Aug 14
2024
Loubet et al., Human Vaccines & Immunotherapeutics, doi:10.1080/21645515.2024.2387221 Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
Retrospective 47 immunocompromised patients in France showing no adverse events with sipavibart, an investigational long-acting monoclonal antibody, as COVID-19 pre-exposure prophylaxis. The patients had various immunosuppressive conditio..
May 17
2024
AstraZeneca, NCT06057064 A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants Having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)
267% higher mortality (p=1) and 33% fewer symptomatic cases (p=0.64). RCT 116 patients in Russia, showing improved nAb titers with sipavibart prophylaxis, but no significant difference for mortality or symptomatic cases.
References
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit